Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$5.94 +3.8%	$4.61	$3.56 ▼ $12.92	$333.58M	0.39	370,623 shs	156,423 shs
IMMX Immix Biopharma	$2.41 +2.3%	$1.99	$1.26 ▼ $3.00	$67.04M	0.31	155,509 shs	39,381 shs
MDWD MediWound	$20.53 +0.5%	$18.97	$12.78 ▼ $24.00	$222.54M	0.38	91,782 shs	31,250 shs
SLDB Solid Biosciences	$5.02 +11.3%	$3.26	$2.41 ▼ $10.37	$390.29M	2.22	1.15 million shs	1.83 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	0.00%	-4.51%	+44.44%	-11.73%	-37.49%
IMMX Immix Biopharma	0.00%	-0.84%	+14.08%	+35.84%	+14.08%
MDWD MediWound	0.00%	-5.46%	-0.29%	+6.97%	+36.32%
SLDB Solid Biosciences	0.00%	-0.66%	+62.82%	-15.86%	-42.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXS Astria Therapeutics	2.1737 of 5 stars	3.6	2.0	2.8	1.7	0.0
IMMX Immix Biopharma	2.6342 of 5 stars	3.5	3.0	2.5	1.7	0.6
MDWD MediWound	2.0566 of 5 stars	3.5	1.0	3.3	0.8	0.6
SLDB Solid Biosciences	3.9016 of 5 stars	4.6	3.0	3.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXS Astria Therapeutics	3.25	Buy	$30.00	405.48% Upside
IMMX Immix Biopharma	3.00	Buy	$7.00	191.06% Upside
MDWD MediWound	3.00	Buy	$31.80	54.90% Upside
SLDB Solid Biosciences	3.23	Buy	$14.90	196.87% Upside

Current Analyst Ratings Breakdown

Latest IMMX, ATXS, MDWD, and SLDB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
6/4/2025	IMMX Immix Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00
5/22/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$16.00
5/19/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
5/16/2025	SLDB Solid Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $10.00
5/16/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$18.00 ➝ $17.00
5/14/2025	ATXS Astria Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$47.00 ➝ $47.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$3.33 per share	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$0.81 per share	N/A
MDWD MediWound	$19.21M	11.55	N/A	N/A	$3.43 per share	5.99
SLDB Solid Biosciences	$8.09M	48.09	N/A	N/A	$6.27 per share	0.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXS Astria Therapeutics	-$72.89M	-$1.87	N/A	N/A	N/A	N/A	-43.58%	-29.36%	8/11/2025 (Estimated)
IMMX Immix Biopharma	-$15.43M	-$0.70	N/A	N/A	N/A	N/A	-102.68%	-80.89%	8/11/2025 (Estimated)
MDWD MediWound	-$6.72M	-$2.09	N/A	N/A	N/A	-142.29%	-82.17%	-33.67%	8/13/2025 (Estimated)
SLDB Solid Biosciences	-$96.01M	-$2.99	N/A	N/A	N/A	N/A	-58.75%	-47.84%	8/12/2025 (Estimated)

Latest IMMX, ATXS, MDWD, and SLDB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/13/2025	Q1 2025	ATXS Astria Therapeutics	-$0.48	-$0.58	-$0.10	-$0.58	N/A	N/A
3/24/2025	Q4 2024	IMMX Immix Biopharma	-$0.25	-$0.16	+$0.09	-$0.16	N/A	N/A
3/19/2025	Q4 2024	MDWD MediWound	-$0.59	-$0.36	+$0.23	-$0.36	$5.79 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXS Astria Therapeutics	N/A	22.38	22.38
IMMX Immix Biopharma	N/A	3.47	3.47
MDWD MediWound	N/A	2.11	1.99
SLDB Solid Biosciences	N/A	7.85	7.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXS Astria Therapeutics	98.98%
IMMX Immix Biopharma	11.26%
MDWD MediWound	46.83%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
ATXS Astria Therapeutics	4.50%
IMMX Immix Biopharma	55.40%
MDWD MediWound	9.20%
SLDB Solid Biosciences	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXS Astria Therapeutics	30	56.43 million	54.80 million	Optionable
IMMX Immix Biopharma	9	27.88 million	14.06 million	Optionable
MDWD MediWound	80	10.81 million	9.79 million	Optionable
SLDB Solid Biosciences	100	77.52 million	35.05 million	Optionable

IMMX, ATXS, MDWD, and SLDB Headlines

Recent News About These Companies

Solid Biosciences Approves Equity Plan Amendment at Meeting

June 13 at 5:13 PM | tipranks.com

Analysts Offer Predictions for SLDB FY2026 Earnings

June 11, 2025 | americanbankingnews.com

Brokers Offer Predictions for SLDB FY2026 Earnings

June 10, 2025 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Shares Sold by Two Sigma Investments LP

June 9, 2025 | marketbeat.com

Solid Biosciences' (SLDB) Market Outperform Rating Reaffirmed at JMP Securities

June 8, 2025 | americanbankingnews.com

Solid Biosciences' (SLDB) "Market Outperform" Rating Reiterated at JMP Securities

June 6, 2025 | marketbeat.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2025 | globenewswire.com

Solid Biosciences Inc. (NASDAQ:SLDB) Short Interest Update

June 3, 2025 | marketbeat.com

Millennium Management LLC Sells 397,321 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)

June 1, 2025 | marketbeat.com

Solid Biosciences’ SWOT analysis: gene therapy stock poised for potential breakthrough

May 28, 2025 | investing.com

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

May 28, 2025 | globenewswire.com

Solid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by Brokerages

May 28, 2025 | marketbeat.com

Research Analysts Set Expectations for SLDB FY2025 Earnings

May 27, 2025 | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Earns "Overweight" Rating from Cantor Fitzgerald

May 24, 2025 | marketbeat.com

Chardan Capital Has Lowered Expectations for Solid Biosciences (NASDAQ:SLDB) Stock Price

May 21, 2025 | marketbeat.com

Q1 Earnings Forecast for SLDB Issued By William Blair

May 21, 2025 | marketbeat.com

Truist maintains buy on Solid Biosciences stock, price target at $16

May 18, 2025 | investing.com

Dimensional Fund Advisors LP Purchases 192,714 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)

May 18, 2025 | marketbeat.com

When Might Solid Biosciences Run Out Of Money?

May 17, 2025 | finance.yahoo.com

Solid Biosciences (NASDAQ:SLDB) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating

May 17, 2025 | marketbeat.com

Solid Biosciences Inc.: Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

May 16, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMX, ATXS, MDWD, and SLDB Company Descriptions

Astria Therapeutics NASDAQ:ATXS

$5.93 +0.21 (+3.67%)

As of 04:00 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Immix Biopharma NASDAQ:IMMX

$2.40 +0.06 (+2.34%)

As of 04:00 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

MediWound NASDAQ:MDWD

$20.55 +0.13 (+0.62%)

As of 04:00 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Solid Biosciences NASDAQ:SLDB

$5.02 +0.51 (+11.31%)

As of 04:00 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time